Through the transient activation of T-cell-enriched cultures from TNBC-derived PBMCs, we have established that the NExT platform is naturally functionalized with the IC receptors PD1, TIM3, and LAG3 that can bind the cognate ligands on tumor cells. Here, LAG3 is linked to neoplasm.